Martin Ladouceur — Fire-cutting healer-magnetizer
Clinical observation reports in vibrational medicine and therapeutic magnetism
Discover rigorously documented real-life cases in vibrational medicine and therapeutic magnetism, observed either remotely or in person. Each case demonstrates a structured clinical approach, objective follow-up, and measurable results for individuals or animals supported in a wide range of conditions.
November 17, 2025 – Clinical Observation: Chemotherapy, Diarrhea, Abdominal Cramps and Neuropathies Under Therapeutic Magnetism
First chemotherapy cycle – therapeutic magnetism and vibrational medicine support, remote intervention over four weeks
December 17, 2025
Clinical introduction
This clinical observation documents a four-week support intervention conducted by Martin Ladouceur, professional healer and therapeutic magnetism practitioner, with a woman undergoing a first cycle of chemotherapy, from November 17 to December 13, 2025. The intervention was provided through therapeutic magnetism and vibrational medicine, as a complementary support approach, without substitution for or interference with medical treatment. The objective was to support the body’s overall adaptive capacity in response to commonly reported chemotherapy side effects, including digestive disturbances, fatigue, and peripheral nerve symptoms.This case is clinically relevant due to a globally favorable tolerance profile, preserved energy levels, and an atypical evolution of peripheral neuropathies, with perceived improvement reported toward the end of the cycle.
Structured Support Methodology
The support was provided remotely, through regular therapeutic magnetism and vibrational medicine interventions, adjusted according to written follow-ups reported by the person throughout the cycle.
The methodology included:
dated written feedback on symptoms and their evolution;
targeted support of digestive comfort and peripheral nervous balance;
maintenance of overall physiological stability and mental clarity.
No medical recommendations were made, and no treatments were altered. This intervention strictly remained within a complementary, non-medical support framework.
Clinical Analysis by Period
Initial Phase – Start of the Cycle (November 17–24, 2025)
November 17, 2025: start of the first chemotherapy cycle (four-week protocol).
November 18, 2025: significant abdominal bloating following a recent 36-oocyte retrieval, identified as an independent aggravating factor.
November 20, 2025: additional intervention prior to chemotherapy session due to persistent abdominal discomfort.
November 21, 2025: marked improvement in abdominal discomfort; migraine and insomnia attributed to medication; one episode of loose stool; energy preserved.
November 24, 2025: ongoing digestive symptoms (diarrhea, cramps, difficult digestion), early satiety; reduced bloating; overall condition acceptable.
Intermediate Phase – Mid-Cycle (November 28–December 1, 2025)
November 28, 2025: one episode of diarrhea post-chemotherapy; overall condition described as very good.
December 1, 2025: onset of finger neuropathies, mainly affecting the right hand; energy and mental state remained stable.
Late Phase – End of the Cycle (December 6–13, 2025)
December 6, 2025: neuropathies present without worsening; one isolated nocturnal diarrhea episode.
December 13, 2025: abdominal cramps and diarrhea controlled with medication; mild headache; perceived improvement in neuropathies (“they seem better, strangely”). Restless legs during treatment attributed to Benadryl.
Clinical Discussion and Interpretive Analysis
During a first chemotherapy cycle, side effects typically show progressive cumulative intensification, particularly digestive and neurological symptoms. In this case, the observed evolution differs from this expected pattern:
digestive symptoms remained manageable throughout the cycle;
no progressive physical collapse was observed;
energy and mental stability were preserved;
subjective improvement of neuropathies at the end of the cycle, which is atypical at this stage.
These observations suggest a globally improved functional tolerance of the treatment. The restless leg symptoms are consistent with a medication-related effect and are not attributable to the support intervention.
Professional Conclusion
Between November 17 and December 13, 2025, this clinical observation highlights a favorable tolerance profile during a first chemotherapy cycle. Digestive symptoms remained manageable, overall energy was preserved, and finger neuropathies showed perceived improvement toward the end of the cycle. These findings are consistent with a structured therapeutic magnetism and vibrational medicine support approach, aimed at reinforcing the body’s adaptive capacity without interfering with medical treatment. At the end of the fourth week, the person expressed the wish to continue chemotherapy without parallel support, in a comparative approach. In my professional framework, this type of support requires continuity, active collaboration, and a clear trust-based relationship, rather than a trial-and-comparison logic.
Under these conditions, the professional decision was made to discontinue the intervention in order to preserve methodological coherence and the integrity of the support framework. This cessation does not invalidate the clinical observations collected during the four-week period, which remain documented and relevant.
Call for Collaboration
This clinical observation is shared for documentation purposes and to encourage collaboration with professionals interested in functional tolerance and complementary support approaches during chemotherapy.
Full Testimonial
Selected excerpts from written follow-ups:
“I feel like my neuropathies are getting better, strangely.” (December 13, 2025)
“My energy level is good and I feel mentally well.” (December 1, 2025)